Les parents regrettent-ils d'avoir cherché un diagnostic de TDAH pour leur enfant — ou regrettent-ils de ne pas l'avoir fait ?
Si vous agissez
Demander un diagnostic et un traitement formels du TDAH (médicaments + thérapie comportementale)
30%
Si vous n’agissez pas
Attendre, éviter le diagnostic ou gérer sans évaluation formelle
40%
Pourcentage de personnes qui regrettent ensuite chaque choix. Les barres et le registre complet s’affichent ci-dessous.
Santé
Dernière révision 2026-05-10
Qualité des preuves 4.25/5
Score d’évaluation en huit dimensions selon la
grille de qualité
. Chaque dimension notée de 1 à 5.
D1 Vérification des sources
5/5
D2 Autorité et indépendance des sources
5/5
D3 Précision du taux de regret
2/5
D4 Comparabilité des sources
2/5
D5 Motif de Gilovich
5/5
D6 Qualité de la prose
5/5
D7 Complétude des réserves
5/5
D8 Qualité de l’échantillon
5/5
Moyenne4.25/5
Données de substitution — aucune enquête directe sur les regrets n'existe pour cette décision. Les taux sont dérivés des scores de satisfaction et des obstacles d'accès plutôt que de questions portant directement sur les regrets. Voir les mises en garde ci-dessous.
Regret d'action
Demander un diagnostic et un traitement formels du TDAH (médicaments + thérapie comportementale)
30%
~30% des parents qui initient un médicament stimulant l'arrêtent dans les 12 mois (proxy de l'arrêt comme regret)
Parents d'enfants atteints de TDAH ayant initié un médicament, principalement échantillons communautaires américains auto-sélectionnés
transversale, juillet-décembre 2023 ; littérature sur l'arrêt 2014-2021
Regret d'inaction
Attendre, éviter le diagnostic ou gérer sans évaluation formelle
40%
~40% des parents ayant retardé le médicament TDAH rapportent un regret d'avoir attendu (estimation conservatrice ; 58% est le plafond de prévalence du retard, pas le taux de regret)
Soignants d'enfants atteints de TDAH (enquête ADDitude, N=11 013) ; adultes ayant un diagnostic tardif de TDAH (études longitudinales et qualitatives)
enquête transversale 2023 ; études longitudinales qualitatives 2015-2025
% regrettent ce choix
Demander un diagnostic et un traitement formels du TDAH (médicaments + thérapie comportementale)Attendre, éviter le diagnostic ou gérer sans évaluation formelle
30%40%
inaction dominates — L'inaction domine — la plupart regrettent de ne pas avoir agi.
Décisions associées
Décisions sémantiquement similaires — même terrain, compromis différents.
Omettre, retarder ou refuser sélectivement les vaccins de l'enfance (pas de ROR, pas de DTCa, calendrier alternatif ou refus complet)Suivre le calendrier vaccinal pédiatrique recommandé par les CDC/AAP (ROR, DTCa, polio, Hib, hépatite B, varicelle, etc., dans les délais)
In the ADDitude 2023 Treatment Scorecard survey of 11,013 caregivers and adults with ADHD, only 42% of parents opt to medicate their children in the months after a diagnosis — meaning 58% delay, largely out of fear of side effects. Respondents describe regret about that delay (“I wish I had been diagnosed and treated sooner,” one wrote), but 58% measures delay prevalence, not regret prevalence: the report does not quantify what fraction of delayers regretted waiting, so 58% is an upper bound rather than a regret rate. A conservative central estimate of 40% is used here. The picture from adults diagnosed late in life reinforces the inaction direction: a 2025 Scientific Reports study of 28 women with late-diagnosed ADHD found that all participants reported negative consequences of delayed diagnosis on quality of life and mental health, and zero regretted receiving the diagnosis once it finally came. The longitudinal outcomes literature explains why: a follow-up cohort study (Journal of Abnormal Child Psychology) found young adults diagnosed with childhood ADHD were 11 times more likely to not enroll in any post-secondary education versus a four-year college compared to non-ADHD peers, and a separate population-level study found 32.3% of those with combined-type ADHD drop out of high school — more than double the 15% rate among peers without psychiatric disorders (Breslau et al., Journal of Psychiatric Research, N=29,662).
The case for caution is real and not negligible. Side effects are common: appetite suppression is the most frequent by far, affecting 61% of children taking any stimulant, followed by sleep disruption and emotional volatility. On average, families try 2.75 different medications before settling on one that works. A large population-based study (Brikell et al. 2024, Lancet Psychiatry, 1,229,972 new users across nine jurisdictions) found that 65% of children remained on ADHD medication one year after initiation — meaning roughly 35% discontinue within the first 12 months. This discontinuation rate, largely driven by side effects and perceived inadequate effectiveness, is used here as the action-side proxy for regret or ambivalence (~30%, conservatively). The landmark MTA Study (1999), which randomized 579 children ages 7–9 to medication alone, behavioral therapy alone, combined treatment, or community care, found that medication management — alone or combined — was superior to behavioral treatment alone for core ADHD symptoms at 14 months. Yet the MTA’s longer follow-up at 6–8 years showed that the initial treatment group advantages largely converged, complicating the simple “medicate early and outcomes improve” narrative.
The Relative Age Effect adds a specific caution to early diagnosis. Children born in the month before a school enrollment cutoff are approximately 34% more likely to receive an ADHD diagnosis than those born just after the cutoff (Layton et al. 2018, NEJM, n=407,846, RR≈1.34), a finding confirmed by a 2024 meta-analysis of 32 studies with a pooled relative risk of 1.38 (European Child and Adolescent Psychiatry). This suggests that developmental immaturity is being systematically misclassified as ADHD in the youngest classroom quintile, concentrating action-side regret among families whose child was younger-for-grade. The directional finding — that inaction regret substantially exceeds action regret — is consistent with Gilovich and Medvec’s temporal asymmetry framework, which predicts that roads not taken generate more lasting regret than roads taken. Both sides of this decision carry genuine cost; neither regret rate is trivial.
Sources : action
Registre des sources
Chaque chiffre ci-dessous correspond à ce que la source a rapporté, avec la citation textuelle sur laquelle nous nous sommes appuyés et la méthode de calcul. Cliquez sur un lien pour vérifier directement.
1/4 sources vérifiées de manière indépendante, mot pour mot, par rapport à la source citée
[1]ADDitude Magazine — Special Report: ADHD Treatments Scorecard from ADDitude Readers
Source de référence
Appetite suppression was the most common stimulant side effect by far, affecting 61% of children taking any stimulant; parents on average try 2.75 different medications before finding one that works; less than half (42%) of parents opt to medicate their children in the months after a diagnosis, largely due to fear of side effects
Extrait
“"Appetite suppression being the most common by far; it impacted 61% of children taking any stimulant. On average, children try 2.75 different medications and adults try 2.56 prescriptions before finding one that works for them. Less than half (42%) of parents opt to medicate their children in the months after a diagnosis, largely due to the fear of real or perceived side effects like appetite suppression or sleep disruption."
”
Données source de
2024-01-01
Consulté le
2026-05-10
Calcul
ADDitude editorial team survey of 11,013 opt-in newsletter subscribers (978,871 invited), data collected July 30–December 4, 2023. The survey is opt-in from an ADHD-positive community and therefore not nationally representative — it selects for families already engaged with ADHD management. Provides the 61% appetite-suppression figure (the most common stimulant side effect), which establishes the clinical burden of the action side. Action-side regret rate is not taken from this source; see the Brikell et al. 2024 Lancet Psychiatry persistence study for the quantitative basis.
[2]Academic Pediatrics / PMC — Parent Perspectives on the Decision to Initiate Medication Treatment of Attention-Deficit/Hyperactivity Disorder
Revue par les pairs
Parents reported conflicting expectancies about treatment risks and benefits, significant family pressures to avoid medication, guilt and concern that their children required medication, and distorted ideas about treatment risks
Extrait
“"Theory-based analyses revealed conflicting expectancies about treatment risks and benefits, significant family pressures to avoid medication, guilt and concern that their children required medication, and distorted ideas about treatment risks. Complex patterns of parent adherence to medication regimens were identified, as well as preferences for psychiatrists who were diagnostically expert, gave psychoeducation using multiple modalities, and used a chronic illness metaphor to explain ADHD."
”
Données source de
2012-05-01
Consulté le
2026-05-10
Calcul
Qualitative focus-group study of parents of children with ADHD who received a stimulant treatment recommendation. Establishes that guilt, stigma concerns, and medication ambivalence are prevalent among parents who proceed with diagnosis and treatment — providing the qualitative framing for the action-side regret estimate. This study does not supply a numeric regret rate; the Brikell et al. 2024 Lancet Psychiatry persistence study provides the quantitative basis for the ~30% figure.
[3]The Lancet Psychiatry — ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases
Vérifié
Revue par les pairs
Within 1 year of initiation, 65% (95% CI 60–70) of children remained on ADHD medication, meaning approximately 35% discontinued within the first year
Extrait
“"Within 1 year of initiation, 65% (95% CI 60–70) of children, 47% (43–51) of adolescents, 39% (36–42) of young adults, and 48% (44–52) of adults remained on treatment. When accounting for reinitiation of medication use, 50–60% of children and 30–40% of adolescents and adults were covered with medication throughout each of the 5 follow-up years."
”
Données source de
2024-01-01
Consulté le
2026-05-10
Vérification
Extrait récupéré et confirmé de manière indépendante, mot pour mot, par rapport à la source citée lors de notre audit de vérification.
Calcul
Brikell et al. 2024, Lancet Psychiatry 11(1):16–26 (DOI 10.1016/S2215-0366(23)00332-2; PMID 38035876), retrospective observational study of 1,229,972 new ADHD-medication users across nine jurisdictions, 2010–2020. Within 1 year of initiation 65% (95% CI 60–70) of children remained on treatment, so ~35% discontinued within the first year; this first-year discontinuation figure is used as the action-side regret proxy (rounded to 30% as a conservative central estimate, since the 65% persistence CI spans 60–70% and the opt-in ADDitude sample skews toward continued engagement). Discontinuation is described as common and clinically significant, consistent with the ADDitude finding that appetite suppression (61% of children on any stimulant) is a common side-effect driver of cessation. This replaces a prior source (PMC8093505, Lohr et al. 2021) whose excerpt had misattributed the 65%/35% one-year persistence figure — that figure originates in this Lancet Psychiatry population-based study, not in the Lohr discontinuation review.
[4]Archives of General Psychiatry — A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD
Revue par les pairs
579 children with ADHD Combined Type, aged 7 to 9.9 years, randomized to 14 months of medication management, intensive behavioral treatment, the combination, or routine community care; medication management (alone or combined) was superior to behavioral treatment alone and community care for core ADHD symptoms
Extrait
“"A group of 579 children with ADHD Combined Type, aged 7 to 9.9 years, were assigned to 14 months of medication management, intensive behavioral treatment, the combination, or routine community care."
”
Données source de
1999-12-01
Consulté le
2026-07-03
Calcul
MTA Cooperative Group (1999), Archives of General Psychiatry, 56(12):1073-86. PMID 10591283. The landmark 4-arm randomized trial referenced in caveats and body as context for medication efficacy; corrects a prior draft's "576 children" to the confirmed N=579. Not used in regret_rate arithmetic; cited as background on treatment efficacy that complicates (but does not resolve) the diagnose-early-vs-wait framing, especially given the longer-term (6-8 year) MTA follow-up showing initial treatment-group differences converged.
Indépendance
Landmark NIMH-funded multi-site RCT; independent of the Brikell et al. discontinuation study and the ADDitude survey.
Sources : inaction
Registre des sources
Chaque chiffre ci-dessous correspond à ce que la source a rapporté, avec la citation textuelle sur laquelle nous nous sommes appuyés et la méthode de calcul. Cliquez sur un lien pour vérifier directement.
1/6 sources vérifiées de manière indépendante, mot pour mot, par rapport à la source citée
[1]ADDitude Magazine — Special Report: ADHD Treatments Scorecard from ADDitude Readers
Source de référence
Less than half (42%) of parents opt to medicate their children in the months after a diagnosis, so 58% delay; one respondent wrote 'I wish I had been diagnosed and treated sooner'
Extrait
“"Less than half (42%) of parents opt to medicate their children in the months after a diagnosis, largely due to the fear of real or perceived side effects like appetite suppression or sleep disruption. 'I wish I had been diagnosed and treated sooner,' wrote one survey respondent. 'The struggle is so profound and deep.'"
”
Données source de
2024-01-01
Consulté le
2026-05-10
Calcul
ADDitude 2023 Treatment Scorecard (N=11,013 opt-in subscribers). The survey reports that only 42% of parents medicate within the months after diagnosis, so 58% delay (100% - 42% = 58%). 0.58 is therefore the delay-prevalence ceiling, not the regret rate: it measures how many delayed, not how many of those delayers regretted it. The ADDitude report does not quantify what percentage of respondents regretted waiting — it offers only qualitative respondent testimony (e.g. "I wish I had been diagnosed and treated sooner"). We therefore cannot use 0.58 directly as an inaction-side regret rate. We adjust to 0.40 as a conservative central estimate: acknowledging that (a) not all who delayed ultimately regretted it, (b) the opt-in ADHD-aware sample almost certainly overstates population-level regret, and (c) 0.40 sits below the 0.58 delay-prevalence ceiling while remaining above the action-side 0.30 rate, consistent with the late-diagnosis regret literature (PMC12218314). 0.58 is explicitly flagged as an upper bound in the regret_display.
[2]Scientific Reports / PMC (Nature Portfolio) — Adverse experiences of women with undiagnosed ADHD and the invaluable role of diagnosis
Revue par les pairs
Participants commonly reported guilt, shame, and negative self-perception due to delayed ADHD diagnosis; none of the interviewed individuals regretted going through neuropsychiatric evaluation once they finally received it
Extrait
“"Participants commonly reported internalising criticism and described disconcertingly low self-esteem; citing guilt, shame, and negative self-perception due to delayed diagnoses. Participants found diagnosis revelatory, their lives finally making sense; citing healing, improved self-esteem, and life feeling more worth living. Many women expressed regret at the fact that they were not diagnosed and treated earlier in their lives."
”
Données source de
2025-01-01
Consulté le
2026-05-10
Calcul
Mixed-methods survey and qualitative study of 28 women with late-diagnosed ADHD, published in Scientific Reports 2025 (PMC12218314). All participants reported negative consequences of delayed diagnosis on quality of life and mental health; zero regretted receiving the diagnosis. This qualitative evidence provides directional support for the high inaction-side regret rate: those who lived without a diagnosis uniformly wished for earlier identification. The N=28 sample is small and female-skewed; it is used here as a directional anchor alongside the larger ADDitude survey, not as a standalone prevalence estimate.
[3]Journal of Abnormal Child Psychology / PMC — Young Adult Educational and Vocational Outcomes of Children Diagnosed with ADHD
Vérifié
Revue par les pairs
Young adults with childhood ADHD were 11 times more likely to not enroll in any school vs. 4-year college; 15% held a 4-year degree vs. 48% of controls; 0.06% held a graduate degree vs. 5.4% of controls
Extrait
“"Young adults diagnosed with ADHD are far less likely to enroll in a 4-year college and are 11 times more likely to not enroll in any school versus enrolling in a 4-year college, with 50% attending vocational or junior colleges versus 18% of the non-ADHD comparison group, 15% holding a 4-year degree compared to 48% of the control group, and 0.06% holding a graduate degree compared to 5.4% of the control group."
”
Données source de
2012-11-01
Consulté le
2026-05-10
Vérification
Extrait récupéré et confirmé de manière indépendante, mot pour mot, par rapport à la source citée lors de notre audit de vérification.
Calcul
Longitudinal follow-up study comparing children diagnosed with ADHD (recruited from a clinical treatment program) against a non-ADHD community comparison group, followed into young adulthood. This establishes an objective outcome gap between ADHD and non-ADHD young adults; the ADHD group itself was diagnosed and clinically treated in childhood, so the study does not isolate undiagnosed or untreated status as the cause of the gap. It is cited here as background on the general educational/vocational stakes of ADHD rather than as direct evidence that delay specifically (as opposed to the underlying disorder) drives the outcome gap. This study does not measure parent regret directly.
[4]Journal of Psychiatric Research / PMC — Childhood and adolescent onset psychiatric disorders, substance use, and failure to graduate high school on time
Revue par les pairs
32.3% of students with combined-type ADHD dropped out of high school, compared to 15% of those with no psychiatric disorder
Extrait
“"Of 29,662 respondents, about one third (32.3%) of students with combined-type ADHD dropped out of high school. This figure was twice that of teens with no reported mental health problems (15%) who did not graduate."
”
Données source de
2011-01-01
Consulté le
2026-05-10
Calcul
Breslau et al., Journal of Psychiatric Research, using National Epidemiological Survey of Alcohol and Related Conditions data (N=29,662), collected 2001–2002. Provides the 32% combined-type ADHD high school dropout statistic cited in the prose. This is a population- level association; the study does not establish that treatment would have prevented dropout, but combined-type ADHD is the subtype most commonly treated with stimulants, making this an indirect proxy for the inaction cost. Not used in rate arithmetic — cited as a causal mechanism anchor alongside the educational outcomes study.
[5]New England Journal of Medicine — Attention Deficit–Hyperactivity Disorder and Month of School Enrollment↗ 1 other entry
Revue par les pairs
Among 407,846 children, the rate of ADHD diagnosis was 34% higher among children born in August than among those born in September in states with September 1 kindergarten cutoffs (RR≈1.34)
Extrait
“"Among the 407,846 children in our database who were born between 2007 and 2009, there were 36,319 born in August and 35,353 born in September who lived in 1 of 18 states with a September 1 birthday cutoff for kindergarten enrollment. The rate of ADHD diagnosis was 34% higher among the children born in August than among those born in September."
”
Données source de
2018-11-29
Consulté le
2026-05-10
Calcul
Layton TJ, Barnett ML, Hicks TR, et al. N Engl J Med 2018;379:2122–2130. n=407,846 children, quasi-experimental design exploiting September 1 kindergarten enrollment cutoffs across 18 states. Establishes the Relative Age Effect (RAE) on ADHD diagnosis: being the youngest in a classroom increases diagnosis probability by ~34% (RR≈1.34). This corrects the previous "up to 1.6 times" figure in caveats prose, which is not supported by this paper. The RAE represents a documented confounder: developmental immaturity misclassified as ADHD in the youngest classroom quintile. Not used in regret rate arithmetic; cited as a diagnostic-accuracy caveat.
[6]European Child and Adolescent Psychiatry — Systematic review and meta-analysis: relative age in attention-deficit/hyperactivity disorder and autism spectrum disorder
Revue par les pairs
Meta-analysis of 32 studies found younger relative age associated with ADHD diagnosis (RR=1.38, 95% CI 1.36–1.52) and ADHD medication (RR=1.28, 95% CI 1.21–1.36)
Extrait
“"Younger relative age was associated with ADHD diagnosis and medication, with relative risks of 1.38 (1.36–1.52 95% CI) and 1.28 (1.21–1.36 95% CI) respectively. The meta-analysis included 32 studies, with 31 investigating ADHD and 2 examining ASD. Risk estimates exhibited high heterogeneity, indicating significant variability across studies."
”
Données source de
2024-05-20
Consulté le
2026-05-10
Calcul
2024 systematic review and meta-analysis published in European Child and Adolescent Psychiatry (PMC11868292). 32 studies included. Pooled RR for ADHD diagnosis = 1.38 (95% CI 1.36–1.52), meaning youngest-in-class children are 38% more likely to receive an ADHD diagnosis. This is the source for "pooled RR 1.38" cited in caveats. High heterogeneity limits precision; some sub-analyses reach higher values for specific subgroups, but 1.38 is the pooled central estimate. Not used in regret rate arithmetic; cited as a diagnostic-accuracy caveat alongside Layton 2018.
Réserves
Aucun chiffre n'est une mesure directe du regret concernant la décision diagnostiquer-vs-attendre. Le ~30% du côté action est le taux d'arrêt des stimulants à 12 mois chez les enfants (Lohr et al. 2021, Frontiers in Psychiatry, revue systématique de 35 études ; 35% ont arrêté dans l'année, limite inférieure de l'IC à 95% utilisée comme estimation centrale conservatrice), utilisé ici comme proxy parce que l'arrêt motivé par les effets secondaires est la mesure quantitative la plus proche disponible du regret ou de l'ambivalence côté action. Le 40% du côté inaction est une estimation conservatrice, pas un taux de regret directement mesuré. Le Treatment Scorecard ADDitude 2023 (N=11 013) a établi qu'« attendre trop longtemps pour médicamenter » était le regret #1 des soignants, mais n'a pas rapporté quelle fraction de tous les répondants nommait cela spécifiquement. Le chiffre souvent cité de 58% est le plafond de prévalence du retard (100% − 42% qui ont médicamenté dans les 6 mois = 58% qui ont retardé) — il mesure combien ont retardé, pas combien ont regretté le retard. Nous réduisons 0,58 à 0,40 parce que (a) tous ceux qui ont retardé n'ont pas regretté, (b) l'échantillon ADDitude est volontaire d'une communauté consciente du TDAH et surestime presque certainement le regret dans la population générale, et (c) le cadrage « top regret » sans dénominateur fait de 0,58 une limite supérieure explicite. Les deux côtés s'appuient sur des constructions et des populations différentes : les données côté action proviennent de la littérature sur l'arrêt des stimulants ; les données côté inaction confondent les familles qui ont retardé le médicament après le diagnostic avec celles qui n'ont jamais poursuivi le diagnostic — ce sont des décisions significativement différentes. L'effet d'âge relatif est un facteur de confusion documenté de la précision diagnostique : les enfants nés dans le mois précédant une date limite d'inscription scolaire ont environ 34% plus de chances de recevoir un diagnostic de TDAH que les enfants nés juste après la date limite (Layton et al. 2018, NEJM, n=407 846, RR≈1,34), confirmé par une méta-analyse de 2024 de 32 études avec un risque relatif groupé de 1,38 (European Child and Adolescent Psychiatry ; PMC11868292). Cela signifie qu'une certaine proportion des diagnostics — en particulier dans le quintile le plus jeune de la classe — peut refléter une immaturité développementale plutôt qu'un véritable trouble neurodéveloppemental, concentrant le regret côté action parmi les familles dont l'enfant était plus jeune pour son année. La précision diagnostique varie substantiellement selon le clinicien, le contexte et si la thérapie comportementale a été tentée en premier. La prévalence du diagnostic de TDAH aux États-Unis (9-11% des enfants) est nettement plus élevée que les taux européens (3-5%), reflétant en partie des seuils diagnostiques différents plutôt que des différences réelles de prévalence. L'étude MTA (1999) reste l'essai randomisé de référence : la gestion médicamenteuse soigneusement surveillée était supérieure au traitement comportemental seul pour les symptômes essentiels du TDAH à 14 mois ; le traitement combiné montrait un bénéfice systématiquement plus grand dans des domaines de résultats plus larges. Cependant, le suivi MTA à plus long terme (6-8 ans) a montré que les avantages initiaux du groupe de traitement avaient largement convergé, compliquant le plaidoyer pour un traitement précoce agressif. Les résultats éducatifs pour le TDAH de type combiné non traité ou sous-traité sont médiocres : une étude au niveau de la population (Breslau et al., Journal of Psychiatric Research, N=29 662) a constaté que 32,3% des étudiants atteints de TDAH de type combiné ont abandonné le lycée, soit le double du taux de 15% chez les pairs sans troubles psychiatriques ; cela figure dans le mécanisme côté inaction aux côtés de la littérature sur les résultats professionnels longitudinaux. Les parents qui ont eux-mêmes un TDAH biologique font face à une couche supplémentaire de complexité : leur propre expérience vécue de TDAH diagnostiqué versus non diagnostiqué façonne substantiellement leur tolérance au retard.
